This Viewpoint discusses the potential risks and benefits for starting screening at 40 rather than 50 years of age and whether clinicians or patients should decide based on risk rather than age.
No takes yet. Share an insight, caveat, or question.
Kerlikowske et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: